FDA approves J&J HIV drug in children

New use approved for Intelence

TITUSVILLE, N.J. — The Food and Drug Administration has approved a drug made by Johnson & Johnson for treating HIV in children.

J&J's Janssen Therapeutics division announced Tuesday the FDA approval of Intelence (etravirine) in patients ages 6 years to younger than 18 years with HIV-1 who have taken other therapies but whose infection has become resistant to treatment. The drug already was approved for adults.

"This indication fulfills an important need in the U.S. among treatment-experienced young children and adolescents living with HIV," Janssen Therapeutics medical director David Anderson said. "This approval also expands the treatment options Intelence offers and reinforces our company's commitment to serving the diverse needs of the HIV treatment community."


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

Login or Register to post a comment.